Ypsomed's ServoPen® for the treatment of Parkinson's disease
Burgdorf, 19 October 2016, 7.00 a.m. – Austrian specialist pharmaceutical company, Ever Pharma, now offers the D-mine Pen for the treatment of Parkinson patients with apomorphine. This reusable pen, which is based on the Ypsomed ServoPen platform, facilitates subcutaneous administration with its patient friendly design.
Apomorphine Hydrochloride (Dacepton) is injected under the skin. It belongs to a group of drugs known as dopamine agonists, which are used for treating Parkinson's disease. Among other things, it helps to shorten ”on-off” phases for late-stage Parkinson patients. "To simplify apomorphine injections for patients, Ever Pharma has decided to use a reusable injection system from Ypsomed. The proven expertise and long experience of Ypsomed in the area of injection systems were the deciding factors for this choice.", is how Georges Kahwati, managing director at Ever Pharma, describes the cooperation with the Ypsomed Group.
The D-mine Pen is currently being launched in Germany and Austria. Other countries, including the Nordic countries, Central America, several states in the Near East, as well as Australia and New Zealand will follow.
For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, by phone at +41 34 424 41 59 or by email (email@example.com).
About Ever Pharma
Ever Pharma is an internationally successful specialist pharmaceutical company focussing on the areas of neurology and intensive care. Ever Pharma operate worldwide in over 70 countries with 25 sales offices and partners. Further information is available at www.everpharma.com or www.d-minecare.com.
About the Ypsomed Group
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business- to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs more than 1’200 employees. Additional information are available under www.ypsomed.com.